Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

Open Forum Infectious Diseases
Michelle L BrownAmanda Paschke

Abstract

In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effective as colistin plus IMI for the treatment of imipenem-nonsusceptible gram-negative infections. Differences in nephrotoxicity were observed between treatment arms. As there is no standard definition of nephrotoxicity used in clinical trials, we conducted analyses to further understand the renal safety profile of both treatments. Nephrotoxicity was retrospectively evaluated using 2 acute kidney injury assessment criteria (Kidney Disease Improving Global Outcomes [KDIGO] and Risk, Injury, Failure, Loss, and End-stage Kidney Disease [RIFLE]). Additional outcomes included time to onset of protocol-defined nephrotoxicity and incidence of renal adverse events. Of 47 participants receiving treatment, 45 had sufficient data to assess nephrotoxicity (IMI/REL, n = 29; colistin plus IMI, n = 16). By KDIGO criteria, no participants in the IMI/REL but 31.3% in the colistin plus IMI group experienced stage 3 acute kidney injury. No IMI/REL-treated participants experienced renal failure by RIFLE criteria, vs 25.0% for colistin plus IMI. Overall, the time to onset of nephrotoxicity varied considerably (2-22 ...Continue Reading

References

Aug 18, 2004·Critical Care : the Official Journal of the Critical Care Forum·Rinaldo BellomoUNKNOWN Acute Dialysis Quality Initiative workgroup
Aug 6, 2010·The Journal of Antimicrobial Chemotherapy·Laura S EliasAlexandre P Zavascki
Sep 9, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason M PogueKeith S Kaye
Oct 5, 2011·The AAPS Journal·Tobias Christian Fuchs, Philip Hewitt
Apr 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emanuele Durante-MangoniRiccardo Utili
Jul 11, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Darowan S AkajagborBruce L Gilliam
Aug 24, 2013·The Lancet Infectious Diseases·L Silvia Munoz-PriceJohn P Quinn
Feb 21, 2014·Revista Brasileira de terapia intensiva·Talita Machado LeviConstança Margarida Sampaio Cruz
Jul 10, 2014·Critical Care : the Official Journal of the Critical Care Forum·Xuying LuoXiuming Xi
Sep 12, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lidia DalfinoNicola Brienza
Nov 27, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger L NationFernanda P Silveira
Nov 5, 2016·American Journal of Infection Control·William R JuddCharles A Kennedy
Jul 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andre C KalilJan L Brozek
Oct 30, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yael Dishon BenattarMical Paul
Nov 30, 2016·Antimicrobial Agents and Chemotherapy·Elizabeth TemkinYehuda Carmeli
Sep 7, 2017·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Tsung-Yu TsaiYung-Chang Chen
Mar 25, 2018·Annals of Clinical Microbiology and Antimicrobials·Ritesh Aggarwal, Arun Dewan
May 31, 2018·Antimicrobial Agents and Chemotherapy·Adeola OkoduwaYanina Dubrovskaya
Feb 21, 2019·The New England Journal of Medicine·James A McKinnellUNKNOWN CARE Study Group

❮ Previous
Next ❯

Citations

Jul 28, 2020·Expert Opinion on Pharmacotherapy·Mohamad MoussaAthanasios Papatsoris
Jan 5, 2021·Current Opinion in Infectious Diseases·Andrew F Shorr, Marya D Zilberberg
Mar 4, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Shi Nae YuSeong Yeon Park
Feb 14, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Hanine MansourLamis R Karaoui
Jul 3, 2021·Antibiotics·Giacomo LuciAntonello Di Paolo
Oct 5, 2021·Infection·Jaffar A Al-TawfiqPatricia Schlagenhauf

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02452047

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

© 2021 Meta ULC. All rights reserved